Vous avez cherché: nintedanib (Maltais - Anglais)

ofev 100 mg kapsuli nintedanib
ofev 100 mg capsules nintedanib

vargatef 100 mg kapsuli nintedanib
vargatef 100 mg capsules nintedanib

is-sustanza attiva hi nintedanib.
the active substance is nintedanib.

ofev 100 mg kapsuli rotob nintedanib
ofev 100 mg soft capsules nintedanib

nintedanib huwa substrat ta' p-gp.
nintedanib is a substrate of p-gp.

ofev fih is-sustanza attiva nintedanib.
ofev contains the active substance nintedanib.

vargatef fih is-sustanza attiva nintedanib.
vargatef contains the active substance nintedanib.

nintedanib ukoll ma kienx substrat ta' bcrp.
nintedanib was also not a substrate of bcrp.

is-sustanza attiva ta' vargatef hi nintedanib.
the active substance of vargatef is nintedanib.

kull kapsula fiha 100 mg ta' nintedanib (bħala esilate)
each capsule contains 100 mg nintedanib (as esilate).

il-kapsuli vargatef fihom is-sustanza attiva nintedanib.
vargatef capsules contain the active substance nintedanib.

studji ġenotossiċi ma indikaw l-ebda potenzjal mutaġeniku għal nintedanib.
genotoxicity studies indicated no mutagenic potential for nintedanib.

l-esponiment għal nintedanib żdied b'mod lineari mal-età.
exposure to nintedanib increased linearly with age.

nintedanib hu substrat ta' p-gp (ara sezzjoni 5.2).
nintedanib is a substrate of p-gp (see section 5.2).

il-konċentrazzjonijiet minimi ta' nintedanib baqgħu stabbli għal aktar minn sena.
nintedanib trough concentrations remained stable for more than one year.

l-għoti flimkien ma' nintedanib għandu jiġi kkunsidrat b'attenzjoni.
co-administration with nintedanib should be carefully considered.

m'hemm l-ebda antidot jew kura speċifika għal doża eċċessiva ta' nintedanib.
there is no specific antidote or treatment for nintedanib overdose.

il-potenzjal għal interazzjonijiet ta' nintedanib ma' kontraċettivi ormonali ma ġiex esplorat.
the potential for interactions of nintedanib with hormonal contraceptives was not explored.

in-nawseja wasslet għal twaqqif ta' nintedanib fi 2.0% tal-pazjenti.
nausea led to discontinuation of nintedanib in 2.0% of patients.

parti żgħira biss tal-bijotrasformazzjoni ta' nintedanib kienet tikkonsisti minn passaġġi ta' cyp,
only a minor extent of the biotransformation of nintedanib consisted of cyp pathways, with